BHSC Stock Overview Operates as a biotechnology company. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
BioHarvest Sciences Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioHarvest Sciences Historical stock prices Current Share Price CA$8.50 52 Week High CA$10.50 52 Week Low CA$6.24 Beta 1.51 1 Month Change -2.30% 3 Month Change 1.19% 1 Year Change 12.96% 3 Year Change -37.73% 5 Year Change n/a Change since IPO 61.90%
Recent News & Updates See more updates
Bioharvest Sciences Inc. Appoints Sharon Malka as Independent Director Jan 22
New minor risk - Market cap size Jan 19
Forecast to breakeven in 2026 Dec 19
BioHarvest Sciences Inc. Launches VINIA Superfood Functional Tea Line Nov 27
Third quarter 2024 earnings released: EPS: US$0 (vs US$0.13 loss in 3Q 2023) Nov 26
Revenues Tell The Story For BioHarvest Sciences Inc. (CSE:BHSC) As Its Stock Soars 26% Nov 17 BioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024
Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director Sep 20
Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023) Aug 30
New major risk - Financial position Aug 30
New minor risk - Market cap size Aug 07 BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding Jun 21
First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023) Jun 05
Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022) May 01
BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024 Apr 05
BioHarvest Sciences Inc.'s (CSE:BHSC) P/S Is On The Mark Mar 17
BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024 Jan 09 BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding Dec 27
Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products Dec 14
Investors Interested In BioHarvest Sciences Inc.'s (CSE:BHSC) Revenues Dec 01 Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023 BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding Oct 20
Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022) Sep 02
BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023 Aug 25 BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding Jul 08
BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board Jun 08
Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023 Jun 01
First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022) Jun 01
BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023 May 19
Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021) Apr 29
BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis Feb 16
Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors Jan 18 BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding Dec 17
Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023 Dec 16
Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021) Nov 29
No independent directors Nov 16
Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021) Aug 30
BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors Jul 01
Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer Jun 01
First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021) May 31
Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020) Apr 29
No independent directors Apr 27 BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding Apr 08
BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022 Apr 07
BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022 Jan 29
Third quarter 2021 earnings: Revenues in line with analyst expectations Dec 01
Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020) Sep 01
Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure Aug 20
BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding Aug 06
BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement Jun 16
First quarter 2021 earnings released Jun 02
Full year 2020 earnings released May 04
Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical Mar 05
Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report Feb 18
New 90-day high: CA$0.57 Feb 11
BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media Feb 10
BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding Feb 03
BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding Jan 22
New 90-day high: CA$0.43 Jan 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In BioHarvest Sciences Inc. (CSE:BHSC) Jan 17
BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board Jan 14
How Much Of BioHarvest Sciences Inc. (CSE:BHSC) Do Insiders Own? Jan 10
New 90-day high: CA$0.21 Dec 30
Third quarter 2020 earnings released: US$0.004 loss per share Nov 29
BioHarvest Sciences Inc. Announces the Appointment of Rhona Applebaum as Its Senior Consultant for Regulatory and Environmental Affairs Nov 11
BioHarvest Sciences Inc. Appoints Roberto Chait to Advisory Board Oct 30
BioHarvest Sciences Inc. announced that it has received CAD 3.807759 million in funding Oct 08
BioHarvest Sciences Inc. Signs Exclusive Sales and Distribution Agreement with Batory Foods Sep 17
BioHarvest Sciences Inc. announced that it expects to receive CAD 3.814208 million in funding Sep 09
First half earnings released Aug 31
BioHarvest Sciences Inc. announced that it has received CAD 0.652379 million in funding Aug 08
BioHarvest Ltd. completed the acquisition of Canna-V-Cell Sciences Inc. (CNSX:CNVC) in a reverse merger transaction. Jul 31 Shareholder Returns BHSC CA Personal Products CA Market 7D 6.3% -0.4% 1.3% 1Y 13.0% -10.2% 21.0%
See full shareholder returns
Return vs Market: BHSC underperformed the Canadian Market which returned 19.1% over the past year.
Price Volatility Is BHSC's price volatile compared to industry and market? BHSC volatility BHSC Average Weekly Movement 6.4% Personal Products Industry Average Movement 10.0% Market Average Movement 8.5% 10% most volatile stocks in CA Market 18.4% 10% least volatile stocks in CA Market 3.0%
Stable Share Price: BHSC has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: BHSC's weekly volatility (6%) has been stable over the past year.
About the Company BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells.
Show more BioHarvest Sciences Inc. Fundamentals Summary How do BioHarvest Sciences's earnings and revenue compare to its market cap? BHSC fundamental statistics Market cap CA$147.29m Earnings (TTM ) -CA$24.56m Revenue (TTM ) CA$32.05m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BHSC income statement (TTM ) Revenue US$22.43m Cost of Revenue US$10.32m Gross Profit US$12.11m Other Expenses US$29.30m Earnings -US$17.19m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.99 Gross Margin 54.00% Net Profit Margin -76.65% Debt/Equity Ratio 28.8%
How did BHSC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 10:24 End of Day Share Price 2025/02/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioHarvest Sciences Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Hunter Diamond Diamond Equity Research LLC Amit Dayal H.C. Wainwright & Co. Anthony Vendetti Maxim Group
